Research on the SARS-CoV-2 virus itself. Covers antiviral trials, antibody neutralization, viral escape, and rapid detection methods.
Researchers developed a new analysis method for CoVerage that predicts SARS-CoV-2 Variants of Concern (VOCs) with a lead time of almost three months. The tool analyzes genomic data to identify antigenic changes in the virus, enabling early detection and characterization of VOCs.
Researchers developed a lyophilized open-source RT-LAMP assay for pathogen detection, making diagnostics more accessible and affordable globally. The assay is heat stable, requires no cold chain, and can detect various pathogens with high sensitivity.
The BA.2.86 Omicron strain was found to have emerged with a high number of genetic mutations in its spike protein, but failed to become a dominant strain. Its sporadic global detection has raised questions about the possibility of laboratory involvement in its emergence.
A new analysis has found a higher risk of arterial and venous thrombosis after COVID-19 infection compared to vaccination. The study also identified an increased risk of thrombosis following the first dose of the AZD1222 vaccine, but not with subsequent doses.
A University of Minnesota research team has found that measuring SARS-CoV-2 in wastewater continues to accurately predict subsequent COVID-19 case counts in a community. The study demonstrates the continued importance of wastewater surveillance for public health planning and informing real-time decision-making frameworks.
A new study reveals that the SARS-CoV-2 nucleocapsid protein can spread between cells, triggering an immune response that mistakenly targets healthy cells. The researchers found that a commonly used anticoagulant, enoxaparin, can block this harmful interaction, potentially offering a new avenue for treatment.
Researchers at EPFL have created ultra-selective aptamers that target specific binding sites on viral spike proteins with unprecedented precision. These multivalent binders show stronger and more selective binding affinities than traditional monovalent binders, making them promising for biomedical diagnostics and therapeutics.
Scientists have modified mRNA vaccines to include the cytokine IL-12, enhancing T cell responses and improving protection against diseases such as SARS-CoV-2, influenza, melanoma, and listeria infection. The study's findings suggest a promising approach to enhance immune stimulation against cancer and other pathogens.
A new technology using microscopic beads marked with stable isotopes enables the simultaneous detection of dozens of different antibodies in hundreds of samples. This expands the capacity of serological analysis for biomedical research, vaccine development, and epidemiological studies.
An international team of researchers has identified a genetic link to long-term symptoms after COVID-19, with a gene variant increasing the risk by about 60%. The variant is located near the FOXP4 gene, which affects lung function and development. Impaired lung function plays a key role in developing long COVID.
A recent study by UFZ reveals that PFAS influence the cellular immune response to SARS-CoV-2, particularly in males. The researchers found that high PFAS exposure alters the immune response, potentially reducing its effectiveness and increasing the risk of poor disease progression.
The study found that mRNA-1083 induced higher immune responses than standard care influenza and COVID-19 vaccines, with an acceptable tolerability and safety profile. The vaccine met noninferiority criteria for all 4 influenza strains and SARS-CoV-2 across various age groups.
Researchers at Karolinska Institutet have identified biomarkers in the blood associated with long COVID symptoms, particularly severe respiratory disorders. The study found that these biomarkers are also linked to inflammatory signal pathways involved in cell death and lung damage.
The CoVaRR-Net network successfully bridged critical research and public health gaps exposed by the COVID-19 pandemic through interdisciplinary collaboration and innovative approaches like wastewater surveillance. Its achievements include 139 peer-reviewed publications, evidence-based public health decisions, and a global leader in ear...
Researchers at UCSF's AViDD Center have developed a highly bioavailable, covalent molecule that inhibits coronavirus MPro with potent in vivo efficacy. This discovery holds promise for preventing future coronavirus pandemics.
Researchers at UCSF's AViDD Center have developed powerful drug candidates that outperformed Paxlovid in preclinical testing against SARS-CoV-2 and MERS. The compounds could inhibit coronaviruses in general, providing a head start against future pandemics.
Long COVID can result in significant health risks for young people, including chronic kidney disease, gastrointestinal symptoms, and cardiovascular conditions. Studies found that children with COVID-19 face elevated risks of developing these conditions, even years after the initial infection.
New research found that COVID vaccines significantly reduced the risk of long COVID in children and adolescents. Vaccination was about 95% effective in preventing long COVID in some cohorts, primarily due to its ability to prevent initial infection.
A large US cohort study found SARS-CoV-2 infection associated with adverse postacute kidney outcomes in children and adolescents, especially those with chronic or acute kidney disease. Long-term monitoring is recommended for these patients.
A study of 113 healthcare workers found that COVID-19 mRNA vaccination induces long-lasting antibody and memory B-cell responses, even in those previously exposed to the virus. The research team also discovered an association between higher levels of specific antibodies and increased risk of breakthrough infections.
A recent study reveals critical vulnerabilities in global testing capacity during the COVID-19 pandemic, with socioeconomic disparities playing a significant role. The findings underscore the need for increased diagnostic capacity, equitable access to healthcare, and sustained international cooperation.
Researchers develop AI model to predict novel mutations in protein sequences, combining grammatical and semantic changes. The method uses all available information about the sequence and mutations to create a more accurate prediction model.
A recent study identifies 11 natural compounds that can inhibit the SARS-CoV-2 spike protein, including caffeine, which exhibits high binding stability and excellent solubility. The discovery highlights the potential of natural products in combating COVID-19 and demonstrates the versatility of widely known compounds like caffeine.
Researchers found that people who later experienced persistent shortness of breath or fatigue had significantly fewer steps per day and a higher resting heart rate before contracting the virus. These findings suggest a link between lower fitness levels and preexisting health conditions in long COVID patients.
Researchers found that women who became pregnant after the start of the pandemic were more likely to experience preterm birth and low birth weight, regardless of COVID-19 infection severity. Moderate-to-severe infections during pregnancy also increased the risk of adverse outcomes.
Researchers developed CeSPIACE, a 39-amino-acid peptide drug candidate that binds to the spike protein, blocking viral entry. It demonstrates strong binding to major SARS-CoV-2 variants and shows efficacy against multiple strains in vivo and in vitro experiments.
A study of the COVICAT cohort found that almost one in four people infected with SARS-CoV-2 developed long COVID, with symptoms persisting for two years or more. Risk factors included severe COVID-19 infection and pre-existing chronic diseases, while vaccination before infection and a healthy lifestyle appeared to reduce the risk.
Researchers at Stanford University have discovered a method to use two antibodies to effectively combat the constantly evolving virus, which could lead to longer-lasting treatments for COVID-19. The antibodies were shown to be effective against all SARS-CoV-2 variants in laboratory testing.
Researchers at Aalto University and others have developed a model that shows smartwatches can accurately detect viral infections several days before symptoms appear. This early detection can lead to significant reductions in disease transmission and could potentially stop a pandemic before it starts.
Researchers developed a new vaccine platform that provides robust, long-lasting protection against multiple flu strains and COVID-19. The vaccine boasts 100% survival rates in vaccinated mice following challenge with either virus.
A nationwide study found that COVID-19 hospital patients experienced a higher rate of deaths from any cause and were more likely to be hospitalized for specific conditions, particularly neurological and respiratory problems. The study also identified increased risks of chronic health complications up to 30 months after discharge.
A new study suggests that mRNA COVID-19 vaccination may protect against post-COVID condition symptoms in children. The findings support the benefits of vaccination beyond acute protection, encouraging increased pediatric uptake.
A study published in Nature Cardiovascular Research identified distinct immune signatures in myocarditis caused by SARS-CoV-2 infection and mRNA vaccines compared to non-COVID-19 myocarditis. The findings suggest a stronger immune response in post-COVID-19 myocarditis, while the inflammation appeared milder in post-vaccination cases.
A US clinical trial will assess the safety and efficacy of a nasal COVID-19 vaccine developed using technology from Washington University in St. Louis. The trial, sponsored by the National Institute of Allergy and Infectious Diseases, aims to evaluate the vaccine's ability to induce strong immunity in the nose and upper respiratory tract.
A new study found that COVID-19 infection is associated with faster growth of plaque in the coronary arteries, leading to an increased risk of cardiovascular events. The study also revealed a higher incidence of high-risk plaques and coronary inflammation among infected patients.
Researchers investigated ozonated water's impact on SARS-CoV-2 in saliva, discovering that protein concentrations like amylase and mucin decrease ozone stability and effectiveness. This study provides insights into the applicability of ozonated water for disinfection in real-world settings.
A study on six serodiscordant couples found that women who were immune to SARS-CoV-2 had elevated expression of the gene IFIT3 compared to their male partners. This suggests that overexpression of IFIT3 may offer protection against COVID-19 by inhibiting viral replication and preventing cell invasion.
Researchers developed a powerful tool to detect SARS-CoV-2 variants with high transmission potential, pinpointing exact mutations driving spread. The model focuses on spike protein and other parts of the virus, enhancing ability to bind human cells and evade immune systems.
Researchers from Osaka University found that Japan's state of emergency declarations led to increased hygienic behaviors and risk perception, which persisted even after the policy was lifted. However, older people became less fearful of COVID-19 and were less likely to wear masks.
A cohort study found COVID-19 to be associated with more severe disease outcomes compared to influenza and RSV during the 2022-2023 season. Vaccination attenuated these differences in severity and long-term mortality rates.
Researchers developed a nanoparticle-based vaccine that generates antibodies targeting conserved regions of sarbecovirus receptor-binding proteins, offering broader protection against multiple strains. The vaccine demonstrated strong antibody responses and protection in animal studies against diverse SARS-CoV-2 and other sarbecoviruses.
Researchers tracked nearly 1,000 people with post-COVID-19 syndrome, finding persistent physical and cognitive impairments that worsened with exercise intolerance. The study's findings support the inclusion of cognitive and exercise testing in clinical evaluation for patients with suspected post-COVID-19 syndrome.
A new method can detect tiny amounts of SARS-CoV-2 virus in blood, stool, and saliva from patients with acute COVID-19 infections. The technology has potential for guiding treatment of long COVID and monitoring viral loads for future infectious diseases.
A recent study published in JAMA Network Open found that females aged 40-55 years have the highest risk of developing long COVID, with a 31% higher associated risk compared to males. The research, part of the NIH RECOVER initiative, suggests that patients and healthcare teams should consider sex differences when treating long COVID.
A research team led by Jianyang Du, PhD, has received a grant to investigate the cellular and molecular mechanisms behind neurological disorders caused by long COVID-19. The study aims to provide insights into how SARS-CoV-2 alters neuronal activity, which could lead to effective therapeutic strategies.
A new study published in the Journal of General Internal Medicine found that COVID-19 infection significantly increases the rate of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) among COVID-19 survivors. Nearly eight times more people with ME/CFS were infected with SARS-CoV-2 than those without, according to the research.
Researchers identified a novel genetic risk factor for SARS-CoV-2 infection, linking a PTPN2 variant to increased ACE2 expression and susceptibility. The study suggests Tofacitinib may mitigate this risk, offering new treatment options for patients at higher genetic risk.
The NIH-funded RECOVER Initiative study reveals a significant association between SARS-CoV-2 infection and an increased incidence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), with 4.5% post-COVID participants meeting ME/CFS diagnostic criteria, compared to 0.6% non-infected participants.
Longidaza significantly reduced exertional desaturation and dyspnea, as well as improved distance walked during the six-minute walk test. The drug's effects on exercise tolerance were sustained for over 100 days after treatment.
Researchers at Indian Institute of Science discover that viruses like SARS-CoV-2 mimic host proteins to trigger excessive cell death and tissue damage in humans. In contrast, bats show mild symptoms despite harbouring similar viruses, highlighting species-specific responses to viral infections.
Researchers at University of Helsinki and colleagues have mapped the 'hijackome', detailing how SARS-CoV-2 variants exploit specific cellular pathways to spread and evade immune defenses.
Scientists at The Jackson Laboratory have identified the CAST/EiJ mouse as a highly susceptible model for studying severe COVID-19. This genetically pure background allows researchers to investigate the virus's impact without artificial receptor modifications, mirroring human responses. Initial trials using antiviral treatments show pr...
Dartmouth researchers propose a new way of thinking about masking and social distancing rules using game theory, considering them as two distinct actions. The study finds that people respond differently to these measures based on their perception of the disease's severity, trending towards masking or no protective action over time.
Researchers have developed a novel therapeutic approach using polypurine hairpins to inhibit the replication of SARS-CoV-2. The technique has shown promising results in laboratory animal models and Vero E6 cells, providing a potential new tool in the fight against COVID-19 and other viral diseases.
An experimental study in mice found that SARS-CoV-2 infection can damage the retinas, leading to long-term implications for vision. The virus caused widespread inflammation across the retinal pigment epithelium, including complement activation and increased production of inflammatory cytokines.
Researchers found that SARS-CoV-2 disrupts mitochondrial reactions, leading to immune sensor activation and a cytokine storm, which triggers multiple organ-damaging events. Autopsy samples revealed extensive inflammation and organ damage in organs such as the heart, lungs, and kidneys.
Researchers have discovered a monoclonal antibody capable of targeting multiple SARS-CoV-2 variants, including recent Omicron strains. K4-66's exceptional ability to adapt to the virus's frequent mutations makes it a promising candidate for vaccine and therapy development.
This study found that certain amino acid substitutions in four IFN-I antiviral pathway proteins can disrupt interactions, potentially aiding in determining SARS-CoV-2 transmission likelihood. Four proteins MDA5, NEMO, IRF3, and ISG15 were identified with potential domains or specific amino acids that may result in PPI disruption.
A study found stopping universal masking and SARS-CoV-2 testing led to a significant increase in hospital-onset respiratory viral infections compared to community cases. Restarting health care worker masks significantly reduced the risk of these infections.
Lysosomal TRAP effectively inhibits virus infection in cell, mouse, hamster, and human lung organoid models, including SARS-CoV-2 and influenza A. It outperforms current standard treatments and is not vulnerable to viral mutations.